Shots:
- Novo Nordisk’s Awiqli (QW basal insulin icodec) has received CHMP’s positive opinion and recommending it for the final approval which is anticipated in next ~67days/ ~2mos
- The opinion was supported by the six P-IIIa (ONWARDS) study assessing the safety & efficacy of Awiqli in type 1 & type 2 diabetes adults (n= >4,000) incl. Real-world analysis
- The study showed superior blood sugar reduction (by HbA1c) & Time in Range (time spent in RBS range) among T2D patients. Awiqli reduced HbA1c, but had a higher hypoglycemia rate
Ref: Novo Nordisk | Image: Novo Nordisk | Press Release
Related News:- Outlook Therapeutics’ Lytena Gains the CHMP’s Positive Opinion for the Treatment of Wet AMD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
